Orchid Pharma Completes Amalgamation with Dhanuka Labs; Sets Record Date July 23
Orchid Pharma's Board approved the amalgamation with Dhanuka Laboratories, effective July 10, 2026. The authorized capital increased to ₹164.51 crore. July 23, 2026, is the record date for share allotment. The exchange ratio is 161 OPL shares for every 5 DLL shares.
Amalgamation is a major corporate restructuring event that will significantly alter the company's capital structure and operations.
The amalgamation is a significant corporate action that is expected to lead to synergies and growth for Orchid Pharma.
Orchid Pharma Limited announced that its Board of Directors, in a meeting held on July 10, 2026, approved several key decisions regarding its amalgamation with Dhanuka Laboratories Limited (DLL). The scheme of amalgamation has become effective from July 10, 2026, with the appointed date for the scheme being April 1, 2024. Consequently, Dhanuka Laboratories Limited stands dissolved without being wound up.
As a result of the amalgamation, the authorized share capital of Orchid Pharma Limited has been increased. Clause V of its Memorandum of Association has been updated to reflect an authorized share capital of ₹164.51 crore (16,45,10,000 equity shares of ₹10 each). The company has also fixed Thursday, July 23, 2026, as the record date to determine the shareholders of Dhanuka Laboratories Limited who will receive shares in Orchid Pharma Limited.
The share exchange ratio for the amalgamation has been set at 161 fully paid-up equity shares of Orchid Pharma (face value ₹10) for every 5 fully paid-up equity shares of Dhanuka Laboratories (face value ₹100).
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under amalgamation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.